Constipation News and Research

Latest Constipation News and Research

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

AMITIZA for treatment of chronic constipation now available in Japan

Sucampo Pharmaceuticals, Inc. and Abbott today announced the availability of AMITIZA (lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases. AMITIZA was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in June.

26 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

KemPharm announces successful Type B meeting with FDA for KP201

KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today a successful Type B meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201.

19 Nov 2012

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).

8 Nov 2012

TD-1211 may relieve opioid-induced constipation

TD-1211 – an inhibitor of the mµ-opioid receptor – alleviates chronic noncancer-related constipation in patients receiving opioid therapy, without affecting pain relief, show the results of a parallel-group study.

2 Nov 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

Patients with chronic constipation at increased risk of colorectal cancer, benign neoplasms

Patients with chronic constipation may be at increased risk of developing colorectal cancer and benign neoplasms, according to study findings unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

22 Oct 2012

EMA CHMP issues positive opinion to Savient's KRYSTEXXA for treatment of chronic gout

Savient Pharmaceuticals, Inc. and its wholly owned subsidiary, Savient Pharma Ireland Limited, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

19 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Dopaminergic treatment has ‘minor impact’ on autonomic symptoms in Parkinson’s

Norwegian researchers say that dopaminergic treatment should be considered for patients with early Parkinson’s disease after finding that dopaminergic medication only has a minor impact on autonomic symptoms after 1 year.

17 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

6 Oct 2012

Botox injections effectively treat urinary urgency incontinence in women

Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).

5 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Constipation News and Research

Latest Constipation News and Research

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

AMITIZA for treatment of chronic constipation now available in Japan

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

KemPharm announces successful Type B meeting with FDA for KP201

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

TD-1211 may relieve opioid-induced constipation

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Possible overlap exists between inflammatory bowel disease and IBS

Patients with chronic constipation at increased risk of colorectal cancer, benign neoplasms

EMA CHMP issues positive opinion to Savient's KRYSTEXXA for treatment of chronic gout

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Dopaminergic treatment has ‘minor impact’ on autonomic symptoms in Parkinson’s

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Oral medication as effective as Botox injections for treating incontinence in women

Botox injections effectively treat urinary urgency incontinence in women

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Constipation News and Research

Latest Constipation News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in